Natera

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Natera 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NTRA

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). 

CEO
Stephen Leonard Chapman
CEOStephen Leonard Chapman
Employees
4,434
Employees4,434
Headquarters
Austin, Texas
HeadquartersAustin, Texas
Founded
2003
Founded2003
Employees
4,434
Employees4,434

NTRA Key Statistics

Market cap
23.12B
Market cap23.12B
Price-Earnings ratio
-88.63
Price-Earnings ratio-88.63
Dividend yield
—
Dividend yield—
Average volume
956.55K
Average volume956.55K
High today
$172.64
High today$172.64
Low today
$167.59
Low today$167.59
Open price
$172.64
Open price$172.64
Volume
852.89K
Volume852.89K
52 Week high
$183.00
52 Week high$183.00
52 Week low
$117.27
52 Week low$117.27

NTRA News

Simply Wall St 6h
How a Legal Settlement and New Rival Test Could Influence Natera’s Competitive Strategy

In the past week, Natera reached an $8.25 million settlement in a legal case and faced heightened competition after Exact Sciences launched a new multi-cancer e...

How a Legal Settlement and New Rival Test Could Influence Natera’s Competitive Strategy
Simply Wall St 5d
A Fresh Look at Natera Valuation After Launch of ARCHER Phase III Bladder Cancer Trial

Natera (NTRA) just made headlines by announcing the activation of the ARCHER phase III trial for muscle-invasive bladder cancer, a major step forward for its fl...

A Fresh Look at Natera Valuation After Launch of ARCHER Phase III Bladder Cancer Trial

Analyst ratings

96%

of 23 ratings
Buy
95.7%
Hold
0%
Sell
4.3%

People also own

Based on the portfolios of people who own NTRA. This list is generated using Robinhood data, and it’s not a recommendation.
TE Connectivity
WisdomTree Japan Hedged E…
iShares Core S&P MidCap ETF
SPDR Euro STOXX 50 ETF
KraneShares CSI China Int…
Booking Holdings
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.